Liraglutide vs Decapeptide-12
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideSkin & Cosmetic
Decapeptide-12- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
- Half-Life
- ~13 hours (once-daily dosing)
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 5 ppm (0.0005%) concentration
- Frequency
- Once daily
- Twice daily (AM and PM)
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Reduces hyperpigmentation and dark spots
- Evens skin tone and improves radiance
- Inhibits post-inflammatory hyperpigmentation
- Well-tolerated alternative to hydroquinone
- Effective for melasma and age spots
- Non-cytotoxic to melanocytes
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Generally very well-tolerated
- Rare mild irritation or sensitivity in some skin types
- Results may take several weeks to become visible
- Stacks With
- —
- —